Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: Study design and rationale of the vision study

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Ji, Li Nong ^a   Pan, Chang Yu ^b   Lu, Ju Ming ^b   Li, Hong ^c   Li, Qiang ^d   Li, Qi Fu ^e   Peng, Yong De ^f   Tian, Hao Ming ^g   Yao, Chen ^h   Zhao, Zhi Gang ⁱ   Zhang, Ru Ya ^j   Wang, Xiang Ling ^j   Wang, Lei ^j  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d HARBIN MEDICAL UNIVERSITY   (China)

^e THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^f SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^g SICHUAN UNIVERSITY   (China)

^h PEKING UNIVERSITY FIRST HOSPITAL   (China)

ⁱ HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^j Beijing SL Pharmaceutical Co Ltd   (China)

more..

Author keywords

DPP IV inhibitors; Study design; Type 2 diabetes; Vildagliptin; VISION study

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; VILDAGLIPTIN;

ARTICLE; BODY MASS; CHINESE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HUMAN; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN;

ADAMANTANE; AGE FACTORS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BODY MASS INDEX; CHINA; CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NITRILES; PROSPECTIVE STUDIES; PYRROLIDINES; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84882563777     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-118     Document Type: Article

References (49)

1. Zinman B. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?. Am J Med 2011, 124(Suppl 1):19-34.
2. World Health Organization Diabetes key facts http://www.who.int/mediacentre/factsheets/fs312/en/index.html, World Health Organization.
3. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, HE J, . China National Diabetes and Metabolic Disorders Study Group Prevalence of diabetes among men and women in China. N Engl J Med 2010, 362:1090-1101. 10.1056/NEJMoa0908292, 20335585, China National Diabetes and Metabolic Disorders Study Group.
4. Niswender K. Early and aggressive initiation of insulin therapy for type 2 diabetes: what is the evidence?. Clin Diabetes 2009, 27:60-68.
5. Lebovitz HE. Type 2 diabetes mellitus - current therapies and the emergence of surgical options. Nat Rev Endocrinol 2011, 7:408-419. 10.1038/nrendo.2011.10, 21301486.
6. McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ, Dahl M. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med 2011, 5:e35-e48. 3205809, 22046219.
7. Group UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
8. Tahrani AA, Bailey CJ, Del PS, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011, 378:182-197. 10.1016/S0140-6736(11)60207-9, 21705062.
9. Filozof C, Schwartz S, Foley JE. Effect of vildagliptin as add-on therapy to a low-dose metformin. World J Diabetes 2010, 1:19-26. 10.4239/wjd.v1.i1.19, 3083880, 21537424.
10. De Jager J, Kooy A, Lehert P, Wulffelé MG, van der Kolk J, Bets D, Verburg J, Donker AJ, Stehouwer CD. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010, 340:c2181. 10.1136/bmj.c2181, 2874129, 20488910.
11. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596. 10.1007/s00125-012-2534-0, 22526604.
12. Del Prato S, Penno G, Miccoli R. Changing the treatment paradigm for type 2 diabetes. Diabetes Care 2009, 32(2):217-222.
13. Halimi S, Schweizer A, Minic B, Foley J, Dejager S. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag 2008, 4:481-492. 2515409, 18827867.
14. Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabet Med 2007, 24:350-358.
15. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000, 108(Suppl 6):15-22.
16. Turner RC, Cull CA, Frighi V. Holman RR; UK Prospective Diabetes Study (UKPDS) Group: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281:2005-2012. 10.1001/jama.281.21.2005, 10359389.
17. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B. Viberti G; ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443. 10.1056/NEJMoa066224, 17145742.
18. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002, 137:25-33. 10.7326/0003-4819-137-1-200207020-00009, 12093242.
19. Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR, Wooddell MJ, Strow LJ. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin 2005, 21:2029-2035. 10.1185/030079905X74844, 16368054.
20. Group UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
21. Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009, 11:506-515. 10.1111/j.1463-1326.2009.01040.x, 19320662.
22. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Båvenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002, 25:869-875. 10.2337/diacare.25.5.869, 11978683.
23. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008, 2:CD006739.
24. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008, 4:753-768. 2597770, 19065993.
25. Kalra S. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes. J Assoc Physicians India 2011, 59:237-245.
26. Mathieu C. The scientific evidence: vildagliptin and the benefits of islet enhancement. Diabetes Obes Metab 2009, 11(Suppl 2):9-17.
27. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004, 89:2078-2084. 10.1210/jc.2003-031907, 15126524.
28. Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovas Diabetol 2012, 11:92.
29. Guerci B, Monnier L, Serusclat P, Petit C, Valensi P, Huet D, Raccah D, Colette C, Quéré S, Dejager S. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab 2012, 38:359-366. 10.1016/j.diabet.2012.06.001, 22809630.
30. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007, 92:1249-1255. 10.1210/jc.2006-1882, 17244786.
31. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005, 90:4888-4894. 10.1210/jc.2004-2460, 15886245.
32. D'Alessio DA, Denney AM, Hermiller LM, Prigeon RL, Martin JM, Tharp WG, Saylan ML, He Y, Dunning BE, Foley JE, Pratley RE. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 2009, 94:81-88. 2630874, 18957505.
33. Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Wang Y, Dunning BE, Foley JE. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008, 10:1114-1124. 10.1111/j.1463-1326.2008.00875.x, 18355325.
34. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007, 76:132-138. 10.1016/j.diabres.2006.12.009, 17223217.
35. Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, Couturier A, Foley JE, Zinman B. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010, 12:780-789. 10.1111/j.1463-1326.2010.01233.x, 20649630.
36. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007, 50:1148-1155. 10.1007/s00125-007-0633-0, 17387446.
37. Ahren B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011, 13:193-203. 10.1111/j.1463-1326.2010.01321.x, 21205107.
38. World Health Organization Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF Consultation 2006, Geneva, Switzerland: World Health Organization, World Health Organization.
39. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Guideline for good clinical practice http://ichgcp.net/, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
40. China Food and Drug Administration Good clinical practice of China http://www.sda.gov.cn/WS01/CL0053/24473.html, China Food and Drug Administration.
41. Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, Tanaka I. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002, 298:779-784. 10.1016/S0006-291X(02)02565-2, 12419322.
42. Hinke SA, Kuhn-Wache K, Hoffmann T, Pederson RA, McIntosh CH, Demuth HU. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002, 291:1302-1308. 10.1006/bbrc.2002.6607, 11883961.
43. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2874-2880. 10.2337/diacare.27.12.2874, 15562200.
44. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005, 28:1936-1940. 10.2337/diacare.28.8.1936, 16043735.
45. Derosa G, Ragonesi PD, Carbone A, Fogari E, D'Angelo A, Cicero AF, Maffioli P. Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients. Pharmacol Res 2013, 73C:20-26.
46. Derosa G, Ragonesi PD, Carbone A, Fogari E, Bianchi L, Bonaventura A. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol Ther 2012, 14:475-484. 10.1089/dia.2011.0278, 22512264.
47. Derosa G, Ragonesi PD, Carbone A, Fogari E, D'Angelo A, Cicero AF, Maffioli P. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin Pharmacother 2012, 13:2581-2591. 10.1517/14656566.2012.734499, 23121473.
48. Pan C, Yoo HJ, Ho LT. Perspectives of CB1 antagonist in treatment of obesity: experience of RIO-Asia. J Obes 2011, 2011:957268. 3021887, 21253513.
49. Wang C, Hou XH, Zhang ML, Bao YQ, Zou YH, Zhong WH, Xiang KS, Jia WP. Comparison of body mass index with body fat percentage in the evaluation of obesity in Chinese. Biomed Environ Sci 2010, 23:173-179. 10.1016/S0895-3988(10)60049-9, 20708495.